Corcept Therapeutics
CORT
59 hedge funds and large institutions have $161M invested in Corcept Therapeutics in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 24 increasing their positions, 6 reducing their positions, and 4 closing their positions.
1,034% more call options, than puts
Call options by funds: $2.64M | Put options by funds: $233K
300% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 6
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
49% more capital invested
Capital invested by funds: $108M → $161M (+$52.6M)
20% more funds holding
Funds holding: 49 → 59 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.36M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$3.49M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.99M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$779K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$3.19M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$197K |
| 3 |
TG
TCW Group
Los Angeles,
California
|
-$125K |
| 4 |
D.E. Shaw & Co
New York
|
-$46K |
| 5 |
Citigroup
New York
|
-$27.7K |
CORT Hedge Fund Activity: Q1 2014 in Review
59 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2014, worth a combined $161M — up 49% from $108M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CORT positions and 4 closed out — a net gain of 11 holders — while 24 added to existing stakes and 6 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.36M. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $3.19M sold.
- 59 institutional investors held Corcept Therapeutics (CORT) as of Q1 2014, up from 49 in Q4 2013.
- Funds reported $161M of Corcept Therapeutics stock for Q1 2014, up 49% quarter-over-quarter.
- 15 funds opened new Corcept Therapeutics positions in Q1 2014 and 4 closed out, a net change of +11 holders.
- The largest Corcept Therapeutics buyer in Q1 2014 was Morgan Stanley, an estimated $4.36M added.
- The largest Corcept Therapeutics seller in Q1 2014 was First Eagle Investment Management, an estimated $3.19M sold.
Based on aggregated 13F filings for Q1 2014.